Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
38
BCDA Quote, Financials, Valuation and Earnings
Last price:
$1.25
Seasonality move
:
-9.27%
Day range:
$1.23 - $1.27
52-week range:
$1.00 - $3.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
17.20x
P/B ratio:
5.13x
Volume:
29.8K
Avg. volume:
64.9K
1-year change:
-45.26%
Market cap:
$13.5M
Revenue:
$58K
EPS (TTM):
-$1.73
Analysts' Opinion
-
Consensus RatingBioCardia, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $15.50, BioCardia, Inc. has an estimated upside of 1120.47% from its current price of $1.27.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.00 representing 100% downside risk from its current price of $1.27.
Fair Value
-
According to the consensus of 2 analysts, BioCardia, Inc. has 1120.47% upside to fair value with a price target of $15.50 per share.
BCDA vs. S&P 500
-
Over the past 5 trading days, BioCardia, Inc. has underperformed the S&P 500 by -2.15% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
BioCardia, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
BioCardia, Inc. revenues have been falling on a year-over-year basis for 7 quarters in a row. In the most recent quarter BioCardia, Inc. reported revenues of --.
Earnings Growth
-
BioCardia, Inc. has grown year-over-year earnings for 9 quarters straight. In the most recent quarter BioCardia, Inc. reported earnings per share of -$0.24.
Enterprise value:
8.8M
EV / Invested capital:
--
Price / LTM sales:
17.20x
EV / EBIT:
--
EV / Revenue:
19.75x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.18x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$430K
Return On Assets:
-209.38%
Net Income Margin (TTM):
-1999.77%
Return On Equity:
-1519.03%
Return On Invested Capital:
-606.53%
Operating Margin:
-54966.67%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $570K | $71K | -- | -- | -- | |
| Gross Profit | $167K | -$354K | -$430K | -$108K | -$107K | |
| Operating Income | -$12.6M | -$7.8M | -$8.6M | -$1.8M | -$1.5M | |
| EBITDA | -$12.2M | -$7.3M | -$8.2M | -$1.6M | -$1.4M | |
| Diluted EPS | -$9.39 | -$4.16 | -$1.73 | -$0.61 | -$0.24 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $17M | $7.2M | $2.1M | $5.1M | $5.4M | |
| Total Assets | $17.3M | $9.2M | $3.7M | $6.3M | $6.1M | |
| Current Liabilities | $3.9M | $3.7M | $3.3M | $2.8M | $3.3M | |
| Total Liabilities | $3.9M | $5.1M | $4.4M | $3.5M | $3.5M | |
| Total Equity | $13.4M | $4.1M | -$660K | $2.8M | $2.6M | |
| Total Debt | -- | $1.4M | $1.1M | $674K | $211K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$11.1M | -$7.3M | -$7.5M | -$2.6M | -$1.7M | |
| Cash From Investing | -$14K | -$5K | -$2K | -$2K | -- | |
| Cash From Financing | $6.3M | $10.4M | $7.9M | $6.1M | $6M | |
| Free Cash Flow | -$11.1M | -$7.3M | -$7.5M | -$2.6M | -$1.7M | |
BCDA
Sector
Market Cap
$13.5M
$28.2M
Price % of 52-Week High
39.69%
51.2%
Dividend Yield
0%
0%
Shareholder Yield
-56.78%
-1.54%
1-Year Price Total Return
-45.26%
-18.1%
Beta (5-Year)
0.666
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.28
200-day SMA
Sell
Level
$1.91
Bollinger Bands (100)
Sell
Level
1.25 - 1.81
Chaikin Money Flow
Buy
Level
6.6M
20-day SMA
Sell
Level
$1.37
Relative Strength Index (RSI14)
Sell
Level
41.01
ADX Line
Sell
Level
19.69
Williams %R
Buy
Level
-82.1429
50-day SMA
Sell
Level
$1.36
MACD (12, 26)
Sell
Level
-0.03
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Neutral
Level
13.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-65.0888)
Sell
CA Score
(Annual)
Level (-14.0279)
Buy
Beneish M-Score
(Annual)
Level (-5.5806)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (15.1643)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
BioCardia, Inc. is a clinical-stage biotherapeutic company, which engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its pipeline includes CardiAMP, CardiALLO, PulmALLO, Helix Biotherapeutic Delivery System, and Morph DNA and Avance Steerable Introducers. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA.
Stock Forecast FAQ
In the current month, BCDA has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BCDA average analyst price target in the past 3 months is $15.50.
-
Where Will BioCardia, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that BioCardia, Inc. share price will rise to $15.50 per share over the next 12 months.
-
What Do Analysts Say About BioCardia, Inc.?
Analysts are divided on their view about BioCardia, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that BioCardia, Inc. is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is BioCardia, Inc.'s Price Target?
The price target for BioCardia, Inc. over the next 1-year time period is forecast to be $15.50 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BCDA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for BioCardia, Inc. is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BCDA?
You can purchase shares of BioCardia, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase BioCardia, Inc. shares.
-
What Is The BioCardia, Inc. Share Price Today?
BioCardia, Inc. was last trading at $1.25 per share. This represents the most recent stock quote for BioCardia, Inc.. Yesterday, BioCardia, Inc. closed at $1.27 per share.
-
How To Buy BioCardia, Inc. Stock Online?
In order to purchase BioCardia, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get BCDA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BCDA
Sector
P/E ratio
--
23.92x
PEG ratio
--
-0.01x
P/B ratio
5.13x
1.83x
Price / LTM sales
17.20x
1.61x
Growth Metrics
BCDA
Sector
Revenue growth
-100%
4.6%
Earnings growth
61.55%
10.88%
Revenue (5-year growth)
-39.41%
6.46%
Earnings forecast
-$0.25
-$0.21
Profitability
BCDA
Sector
Profitability FY 2024
-$372K
$3.5M
Return on invested capital
-606.53%
-31.84%
Return on assets
-209.38%
-27.96%
Return on equity
-1519.03%
-37.63%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Dec
29
Estimated Next Earnings Date
Mar
30
Balance Sheet
BCDA
Sector
Total cash
$5.3M
$26.3M
Short term investments
--
$25.7M
Total assets
$3.7M
$76.9M
Long term debt
$211K
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
